Kenneth To is CEO and Co-Founder of ViewsML Technologies, a TechBio company transforming spatial proteomics for precision medicine and diagnostics using AI-driven virtual biomarker staining.

Kenneth holds a Ph.D. and B.Sc. from the University of British Columbia and an MBA from Simon Fraser University, bringing deep expertise in life sciences and business to his entrepreneurial path.

Kenneth has over 20 years of experience across start-up, mid-size, and multinational life science and pharmaceutical companies, and previously co-founded Wax-it Histology Services, a histopathology contract research organization.

Prior to ViewsML, Kenneth led global strategy, capabilities development, and Key Opinion Leader management at Eli Lilly, and ViewsML has secured backing from investors including Wittington Ventures, Mayo Clinic, Debiopharm, and Providence Health Care Ventures.

ViewsML's platform virtualizes immunohistochemistry to give researchers back 100% of their IHC time and 50% of their budget, representing a 15x ROI, and has established partnerships with leading institutions including Dartmouth Health and Providence Health Care.